Sign Up
|
Sign In
Home
US Market
UK Market
News
My Portfolio
Forex
Forum
Cockpit
EuroTrader
Home
»
World
»
North America
»
United States
»
Biotechnology
»
Vertex Pharmaceuticals Incorpo
Vertex Pharmaceuticals Incorpo
VRTX
(NASDAQ)
Overview
Discussions
Advanced chart
News
Historical data
Recommendations
To view this page ensure that Adobe Flash Player version 10.0.0 or greater is installed.
Industry
:
Health Care
Sector
:
Pharmaceuticals & Biotechnology
$
62.10
Updated
01:10:00
Change %
1.2%
Change
0.7600
Volume
2,933,998
High
$
62.84
Low
$
61.01
Open
$ 61.90
Prev close
$ 61.34
# of shares
-
Market cap
-
Intraday
Market closed
Tech analysis
Market is closed, opens at 14:30
Price development
Latest
1 week
1 month
3 mon
6 mon
1 year
62.10
-2.0%
69.8%
65.2%
122.4%
12.9%
Insufficient flash player version
News about Vertex Pharmaceuticals Incorpo
Subscribe To RSS Feed
Local
International
Announcements
19 April
2nd UPDATE: Gilead, Bristol's Hepatitis C Drugs Show Promise In Study
04 April
2nd UPDATE: Abbott Drugs Suppress Hepatitis C Virus In 2 Studies
04 April
CORRECT: Abbott Drugs Suppress Hepatitis C Virus In 2 Mid-Stage Studies
04 April
UPDATE: Abbott Drugs Suppress Hepatitis C Virus In 2 Studies
04 April
Abbott Drugs Suppress Hepatitis C Virus In 2 Mid-Stage Studies
21 March
Truly Innovative Drug Discovery
05 August
Critical Alerts for Wells Fargo, Alcoa, Hess, Sears, and Vertex Pharmaceuticals Released by Seven Summits Research
29 April
Stock Alerts on Industry Leaders: SYMC, DNDN, ALU, NFLX, VRTX, MHS; Issued by Beacon Equity
15 April
Beacon Equity Issues Trade Alerts on Newsworthy Market Movers: VRTX, ACI, DRH, PX, JNJ, RIMM
12 March
BullMarket.com Updates Outlook on Biotech Stocks
26 February
Beacon Equity Issues Technical Trade Alerts on Drug Manufacturer Stocks: FRX, TEVA, AGN, CEPH, VRTX, ADLR
20 October
Vertex annonce des résultats positifs à 28 jours pour la molécule VX-770, un agent oral d´investigation ciblant une protéine défectueuse responsable de la fibrose kystique
13 December
Resultados provisionales del ensayo clínico PROVE 1 del inhibidor de proteasa de VHC Telaprevir (VX-950)
13 December
Ergebnisse der ersten Zwischenanalyse zu Sicherheit und antiviraler Aktivität aus der klinischen Studie PROVE 1 zum HCV-Proteasehemmer- Prüfpräparat Telaprevir (VX-950)
13 December
Les résultats de l'analyse intermédiaire sur l'innocuité et les antiviraux de l'étude clinique PROVE 1 de Telaprevir (VX-950), un inhibiteur de protéase expérimental pour le virus de l'hépatite C (VHC)
No news for this instrument
More news
Company profile
No description
Version: LiveBranchBuild_20120516.1 - EUROWEB1 - 2012-05-22 02:26:28 - 2012-05-22 01:26:28 - 1000 - Website: OKAY